Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age22-85
SponsorOHH-MED Medical Ltd

About this trial

Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to evaluate device tolerability, followed by continued home use of the device for a total of 6 months. Patients will be instructed to attempt sexual activity periodically over the course of the study. Every time a sexual intercourse is attempted, the patient will be requested to complete an event log using validated assessments. Patients will present for monthly follow-up visits, during which safety will be evaluated and additional efficacy assessments will be performed.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adult, heterosexual, males between 22 and 85 years of age

Subjects diagnosed with organic ED for at least 3 months, according to the American Urology Association (AUA) Guideline Statement 1 (as described in Section 8.1.1 of the study protocol).

Subjects with an IIEF-EF score between 11-21

Steady relationship for at least 3 months

Disqualifiers

Castrate and late onset hypogonadism

History of Priapism or Peyronie's Disease

Surgery or radiotherapy of the pelvic region

Anatomic penile deformations or penile prosthesis

Trial design

Design model

Parallel

Treatments tested in this trial

  • VERTICA Active device

    Device

    VERTICA device with a therapeutic RF energy level

  • VERTICA Sham device

    Device

    VERTICA device with a low, non-therapeutic RF energy level

Treatment groups

98 Participants
are divided into 2 treatment groups
Group A: ActiveExperimental treatment 1 intervention
Group B: ShamSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

A significant difference in the mean change from baseline in the International Index of Erectile Function - Erectile Function domain (IIEF-EF) scores at 12 weeks, between the treatment groups.

The IIEF-EF total score ranges between 6 to 30. A higher total score indicates relatively better erectile functioning.

Time frame
12 weeks
2

A significant change from baseline in the mean International Index of Erectile Function - Erectile Function domain (IIEF-EF) scores at 12 weeks, within the VERTICA Active treatment group.

The IIEF-EF total score ranges between 6 to 30. A higher total score indicates relatively better erectile functioning.

Time frame
12 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.